APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies APG-1387

What's the purpose of this trial?

APG-1387 is a potent, bivalent small-molecule IAP antagonist. APG-1387 has shown strong dose- and schedule-dependent antitumor activities in multiple human cancer xenograft models, APG-1387 also demonstrates its synergistic effect in combination with immune checkpoint inhibitor anti-PD-1 antibody, and such a combinatory effect was further enhanced by chemotherapeutic agent. A total of 35 patients with advanced solid tumors or lymphomas have been treated with APG-1387 in two Phase I dose-escalation studies in Australia and in China Ten dose levels have been tested ranging from 0.3 mg to 45 mg in these 2 studies. Based on the preliminary results, APG-1387 is well-tolerated at the dose levels evaluated to date. APG-1387 is intended for the treatment of patients with advanced solid tumors and hematologic malignancies. After establishing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several Ib /II studies will be implemented accordingly to further access the antitumor effects of APG-1387 in combination with either pembrolizumab or the chemotherapeutic agents.

This trial is currently open and accepting patients.


What will happen during the trial?

Additional Trial Information

Phase 1

Enrollment: 90 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Michigan

University of Michigan Comprehensive Cancer Center

Ann Arbor, MI

Open and Accepting

START Midwest Midwest

Grand Rapids, MI

Open and Accepting

Texas

The START Center - San Antonio South Texas Accelerated Research Therapeutics

San Antonio, TX

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message